ReviewCurrent neuropharmacology2016
From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.
Review in Current neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Methylphenidate for children and adolescents with autism spectrum disorder.The Cochrane database of systematic reviews · 2017Pooled it
- Graph analysis uncovers an opposing impact of methylphenidate on connectivity patterns within default mode network sub-divisions.Behavioral and brain functions : BBF · 2024Trial
- Beyond attention: methylphenidate reduces dishonesty in healthy adults.Psychopharmacology · 2026Article
- Alcohol, flexible behavior, and the prefrontal cortex: Functional changes underlying impaired cognitive flexibility.Neuropharmacology · 2024Review
- Time-dependent affective disturbances in abstinent patients with methylphenidate use disorder.BMC psychiatry · 2022Article
- Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.Neural plasticity · 2021Review
- Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.Arhiv za higijenu rada i toksikologiju · 2020Review
- New Trends of Substance Abuse During COVID-19 Pandemic: An International Perspective.Frontiers in psychiatry · 2020Article
- Neuroenhancement as Instrumental Drug Use: Putting the Debate in a Different Frame.Frontiers in psychiatry · 2020Article
- The Psychonauts' World of Cognitive Enhancers.Frontiers in psychiatry · 2020Article
- Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances.Frontiers in psychiatry · 2020Article
- Pharmacological Human Enhancement: An Overview of the Looming Bioethical and Regulatory Challenges.Frontiers in psychiatry · 2020Review
- Consequences of COVID-19 Lockdown on the Misuse and Marketing of Addictive Substances and New Psychoactive Substances.Frontiers in psychiatry · 2020Article
- Social and Non-Social Cognitive Enhancement in Cocaine Users-A Closer Look on Enhancement Motives for Cocaine Consumption.Frontiers in psychiatry · 2020Article
- Effects of Methylphenidate on Cognitive Function in Adults with Traumatic Brain Injury: A Meta-Analysis.Brain sciences · 2019Article
- Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.Neuropharmacology · 2019Article
- Methylphenidate modifies activity in the prefrontal and parietal cortex accelerating the time judgment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Use of Methylphenidate Analogues as Cognitive Enhancers: The Prelude to Cosmetic Neurology and an Ethical Issue.Frontiers in psychiatry · 2019Article
- [Doping for the brain].Zeitschrift fur Gerontologie und Geriatrie · 2018Review
- How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD). However, a growing number of young individuals misuse or abuse MPD to sustain attention, enhance intellectual capacity and increase memory. Recently, the use of MPD as a cognitive enhancement substance has received much attention and raised concerns in the literature and academic circles worldwide. The prescribing frequency of the drug has increased sharply as consequence of the more accurate diagnosis of the ADHD and the popularity of the drug itself due to its beneficial short-term effect. However, careful monitoring is required, because of possible abuse. In this review different aspects concerning the use of MPD have been approached. Data showing its abuse among college students are given, when the drug is prescribed short term beneficial effects and side effects are provided; moreover studies on animal-models suggesting long lasting negative effects on healthy brains are discussed. Finally, emphasis is given to the available formulations and pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.